规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | T0901317 is a dual LXR/FXR agonist (more potent to LXR than FXR) and an inverse agonist of CAR. T0901317 at concentration ranging in 1-10μM induced FXR target genes BSEP and SHP mRNA expression in a dose-dependent manner in Huh7 cells. The transcription activity of GAL4-hCAR/LBD was repressed by T0901317 with IC50 value of 2.2μM, while the transcription activity of GAL4-LXR/LBD was increased by T0901317 with EC50 value of 0.21μM. A significant repression of Tet-induced CAR:RXR-mediated luciferase activity could also be observed after treatment with 10μM T0901317. Treatment with 10μM T0901317 for 48h reduced hCAR-mediated CYP2B6 expression on mRNA level in HepTR-hCAR cells. |
Concentration | Treated Time | Description | References | |
HepG2 | 0.1 - 0.5 µM | 18 hours | T317 dose-dependently increased REPS2 expression and inhibited the proliferation and migration of HCC cells. | Acta Pharmacol Sin. 2023 Mar;44(3):635-646. |
BNLCL.2 | 0.1 - 0.5 µM | 18 hours | T317 significantly induced REPS2 protein expression in BNLCL.2 cells. | Acta Pharmacol Sin. 2023 Mar;44(3):635-646. |
Huh-7 | 0.1 - 0.5 µM | 18 hours | T317 significantly induced REPS2 protein expression in Huh-7 cells. | Acta Pharmacol Sin. 2023 Mar;44(3):635-646. |
LO2 | 0.1 - 0.5 µM | 18 hours | T317 significantly induced REPS2 protein expression in LO2 cells. | Acta Pharmacol Sin. 2023 Mar;44(3):635-646. |
U2OS cells | 10 µM | 2 days | Inhibited cell proliferation, reduced KI-67 and PCNA protein levels | Cell Death Dis. 2023 Jan 21;14(1):51. |
HOS-MNNG cells | 10 µM | 2 days | Inhibited cell proliferation, reduced KI-67 and PCNA protein levels | Cell Death Dis. 2023 Jan 21;14(1):51. |
Saos-2 cells | 10 µM | 2 days | Inhibited cell proliferation, reduced KI-67 and PCNA protein levels | Cell Death Dis. 2023 Jan 21;14(1):51. |
HEK293 cells | 20 nM | 20 hours | T0901317 induced transcriptional activity of LXR /H9251 with an EC50 of 20 nM, showing higher activity than the endogenous ligand 24,25-EC. | Genes Dev. 2000 Nov 15;14(22):2831-8. |
Primary human monocyte-derived macrophages | 1 µM | 3 hours | T0901317 enhanced the expression of LXR-dependent genes including ABCA1, ABCG1, SMPDL3A, and MERTK. | Cell Death Differ. 2021 Apr;28(4):1301-1316. |
CD4SP thymocytes | 5 µM/ml | 4 hours | To investigate whether LXRβ directly binds to the 5′-regulatory region of the Il7r gene and promotes its transcription | Cell Mol Immunol. 2021 Aug;18(8):1969-1980. |
HL-1 cardiomyocytes | 10 µM | 6 hours | To evaluate the protective effects of T0901317 on LPS-stimulated HL-1 cardiomyocytes, the results showed that T0901317 reversed abnormal cholesterol metabolism, NLRP3 pathway, and inflammatory response. | Bioeng Transl Med. 2023 Apr 6;8(3):e10517. |
HCC cells | 5 µM | 72 hours | T0901317 induced fatty acid synthase (FASN) expression in all HCC cells and antagonized TGF β-induced fibrotic marker responses in a subset of HCC cells. | Oncogenesis. 2019 May 16;8(6):36. |
CAFs | 5 µM | 74 hours | T0901317 induced FASN expression in CAFs and suppressed TGF β-induced myofibroblast gene expression. | Oncogenesis. 2019 May 16;8(6):36. |
Hepatocytes | 10 µM | GF2 significantly reduced T0901317-induced fat accumulation to a similar degree as the control group | J Ginseng Res. 2024 Jan;48(1):89-97. | |
Macrophages | 10 µM | GF2 reduced the expression of pro-inflammatory cytokine genes but did not affect Abca1 expression | J Ginseng Res. 2024 Jan;48(1):89-97. | |
Administration | Dosage | Frequency | Description | References | ||
Mice | LXRβ-deficient mice | Intraperitoneal injection | 0.2 mg/d per mouse | 7 continuous days | To investigate the effect of T0901317 on the survival of SP thymocytes in LXRβ-deficient mice, the results showed that T0901317 promoted the survival of SP thymocytes in the presence of LXRβ, but had no significant effect in LXRβ-deficient mice | Cell Mol Immunol. 2021 Aug;18(8):1969-1980. |
BALB/c Nude mice | Subcutaneous tumour model | Subcutaneous injection | 1 μg | Every 3 days, until the end of the experiment | Inhibited tumour growth, significantly reduced tumour volume and weight | Cell Death Dis. 2023 Jan 21;14(1):51. |
C57BL/6 or Balbc mice | Cecal ligation and puncture (CLP) model | Intraperitoneal injection | 10 mg/kg | Single administration | To evaluate the protective effects of T0901317 on CLP model mice, the results showed that T0901317 significantly reduced sepsis score and improved cardiac dysfunction. | Bioeng Transl Med. 2023 Apr 6;8(3):e10517. |
Mice and hamsters | C57BL/6 mice and Golden Syrian hamsters | Oral | 5 mg/kg | Once daily for 7 days | T0901317 significantly increased plasma triglyceride and phospholipid levels in mice and hamsters by activating LXR, and induced the expression of genes associated with fatty acid biosynthesis. | Genes Dev. 2000 Nov 15;14(22):2831-8. |
C57BL/6 mice | Wild-type mice | Intraperitoneal injection | 5 mg/kg | Once daily for 10 days | T317 significantly increased REPS2 protein and mRNA levels in the liver of mice. | Acta Pharmacol Sin. 2023 Mar;44(3):635-646. |
Mice | High-fat diet-induced MASLD model | Oral | 50 mg/kg | Once daily for 6 weeks | GF2 ameliorated high-fat diet-induced MASLD, reducing hepatic fat accumulation and inflammatory response | J Ginseng Res. 2024 Jan;48(1):89-97. |
Dose | Cynomolgus monkey: 10 mg/kg[4] (p.o.) Rat: 10 mg/kg[5] (p.o.) BALB/c mice: 10 mg/kg - 100 mg/kg[6] (p.o.) |
Administration | p.o. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.08mL 0.42mL 0.21mL |
10.39mL 2.08mL 1.04mL |
20.78mL 4.16mL 2.08mL |
CAS号 | 293754-55-9 |
分子式 | C17H12F9NO3S |
分子量 | 481.33 |
SMILES Code | O=S(C1=CC=CC=C1)(N(CC(F)(F)F)C2=CC=C(C(C(F)(F)F)(O)C(F)(F)F)C=C2)=O |
MDL No. | MFCD03412028 |
别名 | |
运输 | 蓝冰 |
InChI Key | SGIWFELWJPNFDH-UHFFFAOYSA-N |
Pubchem ID | 447912 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
溶解方案 |
DMSO: 105 mg/mL(218.14 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 100 mg/mL(207.76 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|